Bayer and Onyx Report Phase 3 Study Results of NEXAVAR® (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation
Rising interest rates have taken their toll, but as the Fed delays dialing back on stimulus, investors are poised to recapture some of their losses.
The broad stock runup in the first half of 2013 was a boon to ClearBridge Aggressive Growth, and comanager Evan Bauman says that the fund is well-positioned for the market going forward.
We look at how a biotech ETF holds up in an iffy climate for those stocks.
Health-care stocks are on a tear as demand slowly returns.
With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.
Three ways to separate long-term winners from stocks that fizzle.